ATE218872T1 - Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen - Google Patents

Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen

Info

Publication number
ATE218872T1
ATE218872T1 AT96902157T AT96902157T ATE218872T1 AT E218872 T1 ATE218872 T1 AT E218872T1 AT 96902157 T AT96902157 T AT 96902157T AT 96902157 T AT96902157 T AT 96902157T AT E218872 T1 ATE218872 T1 AT E218872T1
Authority
AT
Austria
Prior art keywords
thereach
nsaids
increasing
therapeutic effect
zwitterionic
Prior art date
Application number
AT96902157T
Other languages
English (en)
Inventor
Lenard M Lichtenberger
Bruce D Butler
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/440,417 external-priority patent/US5763422A/en
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE218872T1 publication Critical patent/ATE218872T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT96902157T 1995-01-27 1996-01-24 Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen ATE218872T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37969595A 1995-01-27 1995-01-27
US08/440,417 US5763422A (en) 1995-01-27 1995-05-12 Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
PCT/US1996/000633 WO1996022780A1 (en) 1995-01-27 1996-01-24 Methods of enhancing the therapeutic activity of nsaids and compositions of zwitterionic phospholipids useful therein

Publications (1)

Publication Number Publication Date
ATE218872T1 true ATE218872T1 (de) 2002-06-15

Family

ID=27008731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96902157T ATE218872T1 (de) 1995-01-27 1996-01-24 Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen

Country Status (5)

Country Link
EP (2) EP1214940B1 (de)
AT (1) ATE218872T1 (de)
DE (1) DE69621773T2 (de)
ES (1) ES2176435T3 (de)
WO (1) WO1996022780A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127143A0 (en) 1998-11-19 1999-09-22 Dpharm Ltd Phospholipid terivatives of non-steroidal anti inflammatory drugs
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
CA2431606C (en) * 2000-12-19 2011-07-19 The Board Of Regents Of The University Of Texas System Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CN1852721B (zh) 2003-07-31 2013-03-27 得克萨斯大学体系董事会 用于治疗、预防和/或改善癌症、癌症发病或癌症症状的组合物和方法
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Nsaid-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
EP2760433B1 (de) 2011-09-29 2023-05-31 PLx Opco Inc. Ph-abhängige träger zur gezielten freisetzung von pharmazeutika entlang den gastrointestinaltrakts, zusammensetzungen daraus sowie ihre herstellung und verwendung
EP2797600A4 (de) 2011-12-28 2015-09-16 Pozen Inc Verbesserte zusammensetzungen und verfahren zur abgabe von omeprazol und acetylsalicylsäure
US20130281405A1 (en) * 2012-04-02 2013-10-24 Lenard M. Lichtenberger Use of pc-nsaids to treat and/or prevent pulmonary inflammation
JP2023518822A (ja) 2020-03-26 2023-05-08 ピーエルエックス オプコ インコーポレイテッド pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369182A (en) * 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4421747A (en) * 1978-12-27 1983-12-20 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
DE2914789A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Injizierbare arzneimittel mit entzuendungshemmender wirkung
DE2951142C2 (de) * 1979-12-19 1983-11-03 A. Nattermann & Cie GmbH, 5000 Köln Suppositorium-Zubereitung von Indometacin oder Acemetacin
JP2844756B2 (ja) * 1989-12-01 1999-01-06 日本新薬株式会社 脂肪乳剤
JP3280071B2 (ja) * 1992-05-27 2002-04-30 ポーラ化成工業株式会社 消炎鎮痛外用剤

Also Published As

Publication number Publication date
EP1214940B1 (de) 2009-03-11
DE69621773D1 (de) 2002-07-18
WO1996022780A1 (en) 1996-08-01
EP1214940A1 (de) 2002-06-19
DE69621773T2 (de) 2003-01-02
ES2176435T3 (es) 2002-12-01
EP0805684B1 (de) 2002-06-12
EP0805684A4 (de) 1998-08-05
EP0805684A2 (de) 1997-11-12

Similar Documents

Publication Publication Date Title
DE69637866D1 (de) Methoden zur Erhöhung der Wirksamkeit von nicht-steroidalen antientzündlichen Arzneien und dazu verwendbare Zusammensetzungen enthaltend zwitterionische Phospholipide
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
DE69435086D1 (de) Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen
RU94042899A (ru) Способ достижения болеутоляющего эффекта, способ лечения и профилактики гипертермии у человека, болеутоляющая и жаропонижающая композиции, содержащие оптически чистый r (-) кетопрофен
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
DE69621012D1 (de) VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF
BR9606604A (pt) Composto e método para a fabricação de um medicamento ou para aperfeiçoar o transporte de uma droga ou outro ativo para cruzar as membranas lipidicas no corpo ou assegurar a ação
CA2431606A1 (en) Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
ATE218872T1 (de) Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DK0902789T3 (da) Androstenderivater
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE69617395D1 (de) Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
BR0010808A (pt) Composições farmacêuticas e usos
ATE223204T1 (de) Liposomenzusammensetzung
NO20012944D0 (no) Fosfolipidkomplekser av proantocyanidin A2 som anti- aterosklerotiske midler
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
ATE241974T1 (de) Nimelulide enthaltendes pharmazeutisches präparat zur oralen verabreichung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties